U.S. Cancels $590 Million Deal with Moderna for Bird Flu Vaccine Development

In a recent development, the United States government has officially canceled a $590 million contract with Moderna, a leading biotech company, intended for the development of an avian influenza vaccine. The contract, initially announced on January 17, was aimed at creating an mRNA vaccine targeting the H5N1 bird flu strain, which has been detected circulating among birds and cattle. Experts have expressed concern about the potential of this virus to cross the species barrier and cause a human pandemic.

The cancellation comes during a period of political controversy, with insights suggesting that the move may be linked to opposition from Health Secretary Robert F. Kennedy Jr., who has a history of spreading misinformation regarding vaccines and immunizations. Despite the halt in funding, Moderna announced positive interim results from a Phase 1/2 clinical trial involving 300 participants, which evaluated the vaccine's safety and immune response.

Moderna's CEO, Stephane Bancel, stated that while the loss of government funding introduces uncertainties, the company remains optimistic about the vaccine’s potential, exploring alternative avenues to advance the project. The clinical data underscores the significance of mRNA technology in addressing emerging infectious diseases, including pandemic influenza.

Public health experts, including Dr. Ashish Jha, have criticized the decision, emphasizing the importance of mRNA vaccines, especially given their role during the COVID-19 pandemic. Jha highlighted the impact of Operation Warp Speed, which facilitated the rapid development of mRNA vaccines under President Trump's administration.

This shift raises questions about future strategies for developing vaccines against rapidly emerging viral threats and highlights the evolving landscape of public-private partnerships in pandemic preparedness.

Source: https://medicalxpress.com/news/2025-05-cancels-million-moderna-bird-flu.html